Abstract:In patients with non-small cell lung cancer (NSCLC), the standard therapy consists of selective tyrosine kinase inhibitors that target epidermal growth factor receptors (EGFR). Nonetheless, their clinical utility is primarily limited by the development of resistance to drugs. HDAC inhibitors have been shown in studies to reduce the level of EGFR that is expressed and downregulate the EGFR-induced phosphorylation of AKT and ERK. Therefore, dual inhibitors of EGFR and HDAC provide a potential approach as combination treatment synergistically inhibited the growth of NSCLC. Herein, we examined the EGFR inhibition effect of twenty compounds which designed and synthesized by us previously. Among them, compounds 12c and 12d exhibited powerful antiproliferative activity against the NCI–H1975 cell line with IC 50 values of 0.48 ± 0.07 and 0.35 ± 0.02 μM, correspondingly. In cell-free kinase assays, both 12c and 12d demonstrated target-specific EGFR inhibition against wild type (EGFR wt ). Furthermore, the expression of EGFR and phosphorylation of the EGF-induced pathways were significantly suppressed under the treatment of 12c and 12d . Besides, both histones H3 and H4 exhibited increased levels of acetylation following 12c and 12d treatment. The animal experiments shown that 12d could prevent the growth of tumor, inhibited the expression of EGFR and the phosphorylation levels of p70 S6K, AKT and p38 MAPK in vivo , and did not cause organ damage to the mice during the experiment. Overall, the results illustrated that compound 12c and 12d could serve as effective EGFR and HDAC dual inhibitors in NSCLC cells. Our work offers an alternative strategy for NSCLC therapy.

Synthesis and Biological Evaluation of N-Aryl Salicylamides with A Hydroxamic Acid Moiety at 5-Position As Novel Hdac-Egfr Dual Inhibitors

Synthesis and Biological Evaluation of 1-(2-Aminophenyl)-3-arylurea Derivatives as Potential EphA2 and HDAC Dual Inhibitors.

Synthesis, biological evaluation and molecular docking studies of new pyrimidine derivatives as potent dual EGFR/HDAC inhibitors

Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.

Design, Synthesis and Biological Evaluation of Salicylamide Analogues As Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Synthesis and Biological Evaluation of a Series of Novel Salicylanilides As Inhibitors of EGFR Protein Tyrosine Kinases

Design, Synthesis And Biological Evaluation Of Novel Osimertinib-Based Hdac And Egfr Dual Inhibitors

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Discovery of 4-((3,4-dichlorophenyl)amino)-2-methylquinolin-6-ol derivatives as EGFR and HDAC dual inhibitors

Design, Synthesis and Biological Evaluation of HDAC and VEGFR Dual Inhibitors as a Multi-targeted Anticancer Agents

Synthesis and Anti‐Proliferation Activity Evaluation of Novel 2‐chloroquinazoline As Potential EGFR‐TK Inhibitors

Synthesis and antiproliferative activities against Hep-G2 of salicylanide derivatives: potent inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase.

Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents

Design, Synthesis and Biological Evaluation of Novel Egfr/Her2 Dual Inhibitors Bearing A Oxazolo[4,5-G]Quinazolin-2(1h)-One Scaffold

Synthesis, Biological Evaluation and Molecular Docking Studies of 3-(1,3-diphenyl-1h-pyrazol-4-yl)-n-phenylacrylamide Derivatives As Inhibitors of HDAC Activity.

Synthesis and Biological Evaluation of Thiophene-Based Hydroxamate Derivatives As HDACis with Antitumor Activities

Design, Synthesis and Biological Evaluation of 4-Anilinothieno[2,3-d]pyrimidine-based Hydroxamic Acid Derivatives As Novel Histone Deacetylase Inhibitors.

Design, Synthesis and Biological Evaluation of Isoquinoline-Based Derivatives As Novel Histone Deacetylase Inhibitors

Design, Synthesis and Biological Evaluation of Novel Benzoylimidazole Derivatives As Raf and Histone Deacetylases Dual Inhibitors.

Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors